Shots: The approval is based on a P-III study evaluating the safety, PK & efficacy of Trikafta in 66 children aged 6-11yrs. old with CF with either two copies of […]readmore
Shots: Vertex’ new drug submission for Trikafta has been accepted for Priority Review by Health Canada for the treatment of CF in people aged ≥12yrs. With PR, the conventional review […]readmore
Shots: The two P-III studies involve assessing of Trikafta in 403 & 107 patients aged ≥12yrs. with CF with one F508del mutation and one minimal function mutation (F/MF) in the […]readmore
Shots: The approval is based on two global P-III studies assessing Trikafta in 403 & 107 patients with CF aged ≥12yrs. with at least one F508del mutation and one minimal […]readmore
Copyright © 2020 Digiqole. All Right Reserved.